Sorrento reports positive clinical results for COVID-19 stem cell treatment

By The Science Advisory Board staff writers

April 20, 2021 -- Sorrento said that all 10 of the COVID-19 patients receiving its stem cell treatment in a phase IB study were discharged from the intensive care unit (ICU) within three days after their last infusion.

The single-arm, nonrandomized phase IB study (MSC-COV-10) investigated the safety and preliminary efficacy of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) in treating COVID-19-induced acute respiratory failure or acute respiratory distress syndrome. COVI-MSCs were administered every other day for up to three infusions and a total of 1,000,000 cells/kg. Patients were followed for 28 days after the final infusion, and no infusion-related adverse events were observed, according to the company.

A pivotal placebo-controlled study is now being planned at multiple sites in the U.S. and Brazil to support an emergency use authorization submission, Sorrento said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?